Multiple Sclerosis (MS) Mouse Models

Biospective's multiple sclerosis animal models (EAE & cuprizone) are optimized for translational neuroscience drug development. These mouse models feature demyelination, inflammatory infiltrates, microgliosis, astrogliosis, and axonal injury. Readouts include clinical & motor assessments, fluid biomarkers (e.g. NfL, cytokines), in vivo imaging (MRI), and quantitative IHC/IF. As a neuroscience CRO, Biospective provides efficacy, MoA, and target-engagement studies in these MS mouse models.

Biospective specializes in mouse models of multiple sclerosis (MS) that replicate key features of human MS, with substantial expertise in neuroimmunology. As a global preclinical contract research organization, we support biotech and pharmaceutical drug development programs using validated multiple sclerosis rodent models for therapeutic efficacy, mechanism-of-action, target engagement, and PK/PD studies across small molecules, antisense oligonucleotides (ASOs), gene therapy (AAVs), antibodies, and other biologics. With fully integrated, end-to-end preclinical services, Biospective facilitates translational MS research from study design through data interpretation.

Multiple Sclerosis Mouse Models – Our Core Expertise

Biospective specializes in disease-relevant MS mouse models for drug development.

Demyelination and inflammation are defining features of multiple sclerosis. As part of our neuroinflammation models portfolio, Biospective has built specialized capabilities around multiple sclerosis animal models.

At Biospective, we use both EAE mice and cuprizone mice to model different aspects of human MS. EAE models autoimmune-mediated demyelination and axonal damage, while cuprizone models demyelination & remyelination without peripheral inflammation. Our in vivo services are focused on reproducibility, well-defined model phenotypes, and the integration of clinical, motor, imaging, biochemical, molecular, and quantitative IHC/IF endpoints to enable comprehensive in vivo MS model efficacy studies and exploration of mechanism-of-action.

Which Features of Biospective's Multiple Sclerosis Disease Models are Translatable to Human Disease?

Why Choose Biospective as Your MS Models CRO?

Biospective is a neuroscience CRO with a focus on MS animal models, strong scientific expertise, and extensive experience conducting preclinical studies with multiple sclerosis models.

• Specialized Multiple Sclerosis CRO: Focused on MS and neuroinflammatory disease models, not a generalist animal provider.

• Multiple Validated MS Models: EAE and cuprizone mouse models are readily available for studies.

• Multiple Sclerosis Expertise: Deep scientific expertise in multiple sclerosis biology and pathology.

• Integrated Services: Fully integrated preclinical services from study design to data interpretation, ensuring seamless execution.

• Proven Efficacy Data: Industry-standard EAE & cuprizone models efficacy datasets and extensive historical controls for robust benchmarking.

• Accelerated Timelines: Rapid study initiation and efficient workflows to compress timelines without sacrificing quality.

• Translational Biomarkers: Advanced biomarkers (MRI, PET imaging, CSF/blood assays) that bridge preclinical findings to clinical outcomes.

• Flexible & Customized Study Designs: Our scientists work with your team to customize the study design to best fit your goals.

• Global Support: Experience supporting biotech and pharma clients worldwide, with responsive project management and communication.

Our scientists work as an extension of your internal team, collaborating closely to ensure scientific rigor, reproducibility, and translational relevance at every stage of your MS research program.

End-to-End Multiple Sclerosis Models Preclinical CRO Services

Biospective offers fully integrated preclinical contract research services.

• Study design & model selection – expert guidance on choosing the right MS model and designing robust studies

• In vivo efficacy studies – execution of treatment studies with comprehensive monitoring of outcomes

• Biodistribution & PK/PD – analysis of drug distribution and pharmacokinetics/pharmacodynamics in CNS and periphery

• Target engagement assays – confirmation that the therapeutic hits its molecular target (e.g. remyelination, reduced inflammation)

• Clinical & motor scoring – measures such as the EAE Score

• In vivo multi-modality imaging – MRI, PET, SPECT, fluorescence, and bioluminescence imaging to track disease and treatment effects

• Immunoassays – biomarker quantification in CSF, blood, and tissue (e.g. NfL, cytokines, chemokines)

• Immunohistochemistry (IHC) & multiplex immunofluorescence (mIF) – post-mortem tissue staining & quantitative image analysis to assess pathology and therapeutic impact

• Data analysis & reporting – rigorous quantitative analysis, statistics, and comprehensive reporting by our scientists

This end-to-end approach minimizes handoffs, accelerates timelines, and reduces risk for our sponsors by keeping all aspects of the study with one expert team.

How are MS Mouse Models Used in Drug Development?

We work closely with our biotech and pharma sponsors to:

• Evaluate therapeutic efficacy and dose-response in MS models

• Assess target engagement and disease-modifying effects

• Support translational biomarker strategies, including imaging and fluid biomarkers for clinical readiness

Our MS mouse models are optimized for in vivo testing of multiple therapeutic modalities, including both traditional and advanced approaches: